Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 5Glioblastoma 4Breast Neoplasms 4Melanoma 3Pathologic Complete Response 2Ovarian Neoplasms 2Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Gliosarcoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Glioma 1Breast Neoplasms, Male 1Brain Neoplasms 1Advanced Ovarian Cancer 1Advanced Cancer 1

Interventions

Nivolumab 19Ipilimumab 9linrodostat 6relatlimab 4Pemetrexed 4Paclitaxel 4Carboplatin 4ARRY-334543 4Docetaxel 3regorafenib 2anlotinib 2abemaciclib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Gemcitabine 2Cyclophosphamide 2Capecitabine 26-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2vorolanib 1trametinib 1tislelizumab 1sargramostim 1ralimetinib 1prexasertib 1palifosfamide lysine 1p38 Mitogen-Activated Protein Kinases 1mirdametinib 1lirilumab 1indibulin 1gedatolisib 1fluzoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Cancer × sargramostim × Clear all
NCT02383212 2020-01-27

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Regeneron Pharmaceuticals

Phase 1 Completed
398 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡